Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

By Mohamed Somaia   Rosenheck Robert   Harpaz-Rotem Ilan   Leslie Douglas   Sernyak Michael  

Psychiatric Quarterly, Vol. 80, Iss. 4, 2009-12 ,pp. : 241-249

Springer Publishing Company

Access to resources Recommend Favorite

Risperidone long-acting injection, a promising treatment for patients with bipolar disorder

By Dratcu Luiz   Bamelis Dominiek   Libretto Susan  

Journal of Mental Health, Vol. 14, Iss. 5, 2005-10 ,pp. : 523-529

Informa Healthcare

Access to resources Recommend Favorite

Risperidone long-acting injectable for maintenance therapy in bipolar disorder: An open-label pilot study

By Braunig Peter   Sacchetti Emilio   Medori Rossella  

International Journal of Psychiatry in Clinical Practice, Vol. 12, Iss. 1, 2008-01 ,pp. : 74-77

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg

By Mauri Massimo Carlo   Turner Martin   Volonteri Lucia   Medori Rossella   Maier Wolfgang  

International Journal of Psychiatry in Clinical Practice, Vol. 13, Iss. 1, 2009-03 ,pp. : 36-47

Ashgate Publishing Ltd

Access to resources Recommend Favorite

A descriptive, open-label, long-term follow-up survey of psychotic patients receiving risperidone long-acting injectable: Preliminary results

By Viala Annie   Cornic Francoise   Benamor Cyrine   Baldacci Chantal   Cheref Smail   Gauillard Jacques   Martin Pascal   Caroli Francois   Vacheron Marie Noëlle  

International Journal of Psychiatry in Clinical Practice, Vol. 13, Iss. 2, 2009-06 ,pp. : 138-146

Ashgate Publishing Ltd

Access to resources Recommend Favorite